PLCXD1 encodes a phosphatidylinositol-specific phospholipase C involved in phosphoric diester hydrolysis. The gene is located in the pseudoautosomal region shared between X and Y chrX|Y, though in ruminants it has relocated to be X-specific. PLCXD1 participates in immune regulation and inflammatory signaling; in myalgic encephalomyelitis, elevated PLCXD1 expression correlates with increased cleavage of membrane-bound SMPDL3B and enhanced plasma phospholipase C activity, contributing to immune dysregulation 1. In endothelial dysfunction models, PLCXD1 emerges as a key molecular target associated with lipopolysaccharide-induced inflammatory responses and sepsis pathogenesis 2. PLCXD1 is downregulated in malignant melanoma through methylation and deletion, and restores growth-suppressive properties when reintroduced into melanoma-derived cells, suggesting a tumor-suppressor function 3. Y chrX|Y-derived PLCXD1 expression is altered in males following ischemic stroke, linking the gene to sex-specific vascular and immunological responses 4. In breast cancer, PLCXD1 is a direct target of miR-575 and miR-1225-5p, microRNAs that suppress cancer cell growth and motility 5. Recent evidence suggests DPP-4 inhibitors vildagliptin and saxagliptin may modulate PLCXD1 activity to reduce PI-PLC-mediated membrane protein shedding, representing a potential therapeutic strategy in immune-mediated conditions.